Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says

Like
Comment
Favorite

Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says

MT Newswires Live09-04 23:17

Climb Bio's (CLYM) data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was "positive," Wedbush analysts said in a Friday note.

Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.

Some investors were looking for a more clear-cut "winner" between Climb Bio and Jade Biosciences (JBIO) in their nephropathy clinical trials, Wedbush said.

Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.

Wedbush kept its outperform rating and a $25 price target on the stock.

Shares of the company were up nearly 8% in Friday trading.

Price: 15.75, Change: +1.16, Percent Change: +7.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2664358323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664358323","market":"hk","top_or_hot":-1,"title":"Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a>'s (CLYM) data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was \"positive,\" Wedbush analysts said in a Friday note.</p><p>Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.</p><p>Some investors were looking for a more clear-cut \"winner\" between Climb Bio and <a href=\"https://laohu8.com/S/JBIO\">Jade Biosciences</a> (JBIO) in their nephropathy clinical trials, Wedbush said.</p><p>Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.</p><p>Wedbush kept its outperform rating and a $25 price target on the stock.</p><p>Shares of the company were up nearly 8% in Friday trading.</p><p>Price: 15.75, Change: +1.16, Percent Change: +7.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-04 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a>'s (CLYM) data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was \"positive,\" Wedbush analysts said in a Friday note.</p><p>Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.</p><p>Some investors were looking for a more clear-cut \"winner\" between Climb Bio and <a href=\"https://laohu8.com/S/JBIO\">Jade Biosciences</a> (JBIO) in their nephropathy clinical trials, Wedbush said.</p><p>Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.</p><p>Wedbush kept its outperform rating and a $25 price target on the stock.</p><p>Shares of the company were up nearly 8% in Friday trading.</p><p>Price: 15.75, Change: +1.16, Percent Change: +7.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JBIO","symbol_name":"Jade Biosciences","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664358323","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664358323","pubTimestamp":1788535063,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Climb Bio's  data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was \"positive,\" Wedbush analysts said in a Friday note.Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.Some investors were looking for a more clear-cut \"winner\" between Climb Bio and Jade Biosciences  in their nephropathy clinical trials, Wedbush said.Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.Wedbush kept its outperform rating and a $25 price target on the stock.Shares of the company were up nearly 8% in Friday trading.Price: 15.75, Change: +1.16, Percent Change: +7.95","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JBIO":"Jade Biosciences","CLYM":"CLIMB BIO INC","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Wedbush 表示，Climb Bio 的 IgA 肾病试验 1 期数据“积极”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JBIO":1,"CLYM":1},"content_text":"Climb Bio's (CLYM) data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was \"positive,\" Wedbush analysts said in a Friday note.Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.Some investors were looking for a more clear-cut \"winner\" between Climb Bio and Jade Biosciences (JBIO) in their nephropathy clinical trials, Wedbush said.Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.Wedbush kept its outperform rating and a $25 price target on the stock.Shares of the company were up nearly 8% in Friday trading.Price: 15.75, Change: +1.16, Percent Change: +7.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}